2. Search Result
Search Result
Results for "

Plasmodium falciparum parasite

" in MedChemExpress (MCE) Product Catalog:

56

Inhibitors & Agonists

1

Fluorescent Dyes

1

Peptides

7

Natural
Products

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-143218
    TPE-MI
    10+ Cited Publications

    Tetraphenylethene maleimide

    		 Huntingtin Parasite Infection Neurological Disease
    TPE-MI (Tetraphenylethene maleimide) is a thiol probe for measuring unfolded protein load and proteostasis in cells (the excitation wavelength is 350 nm and the emission wavelength is 470 nm). TPE-MI can report imbalances in proteostasis in induced pluripotent stem cell models of Huntington disease, as well as cells transfected with mutant Huntington exon 1 before the formation of visible aggregates. TPE-MI also detects protein damage following dihydroartemisinin research of the malaria parasites Plasmodium falciparum .
    TPE-MI
  • HY-B0148
    Risedronic acid
    2 Publications Verification

    Risedronate

    		 Parasite Apoptosis Infection Metabolic Disease Cancer
    Risedronic acid (Risedronate) is a bisphosphonate and potent antiresorptive agent. Risedronic acid induces Apoptosis. Risedronic acid inhibits the transfer of farnesyl pyrophosphate groups to parasite proteins. Risedronic acid inhibits osteoclast-mediated bone resorption and alters bone metabolism. Risedronic acid inhibits blood-stage Plasmodium falciparum (IC50 of 20.3 μM) .
    Risedronic acid
  • HY-103397
    Nanaomycin A
    4 Publications Verification

    		 Antibiotic DNA Methyltransferase Parasite Infection Cancer
    Nanaomycin A is the first selective DNMT3B inhibitor with an IC50 of 500 nM. Nanaomycin A, a quinone antibiotics, reactivates silenced tumor suppressor genes in human cancer cells . Nanaomycin A inhibits in vitro growth of the human malaria parasite Plasmodium falciparum with an IC80 value of 33.1 nM .
    Nanaomycin A
  • HY-103353
    SID 26681509
    5 Publications Verification

    		 Cathepsin Parasite Infection Cancer
    SID 26681509 is a potent, reversible, competitive, and selective inhibitor of human cathepsin L with an IC50 of 56 nM. SID 26681509 inhibits in vitro propagation of malaria parasite Plasmodium falciparum and inhibits Leishmania major with IC50s of 15.4 μM and 12.5 μM, respectively. SID 26681509 shows no inhibitory activity against cathepsin G .
    SID 26681509
  • HY-B0119
    Risedronic acid sodium
    2 Publications Verification

    Risedronate sodium

    		 Parasite Apoptosis Infection Metabolic Disease Cancer
    Risedronic acid (Risedronate) sodium, a bisphosphonate, is a potent anti-resorption agent that inhibits osteoclast-mediated bone resorption and changes the bone metabolism. Risedronic acid sodium suppresses osteoblast differentiation and induced caspase- and isoprenoid depletion-dependent apoptosis. Risedronic acid sodium inhibits blood stages of Plasmodium falciparum (IC50 of 20.3 μM). Risedronic acid sodium inhibits the transfer of the farnesyl pyrophosphate group to parasite proteins .
    Risedronic acid sodium
  • HY-12912
    KDU691

    		PI4K Parasite Infection
    KDU691, an imidazopyrazine with potent anti-parasitic activity against blood stage schizonts, gametocytes and liver stages, is a Plasmodium PI4K inhibitor. KDU691 selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites .
    KDU691
  • HY-B0529A
    Azlocillin sodium salt
    1 Publications Verification

    Sodium azlocillin

    		 Bacterial Parasite Antibiotic Infection
    Azlocillin sodium salt (Sodium azlocillin), a semisynthetic penicillin, is a broad spectrum β-lactam antibiotic. Azlocillin sodium salt shows antipseudomonal activity, and also potent against the malarial parasite Plasmodium falciparum .
    Azlocillin sodium salt
  • HY-129476
    L-Canaline

    		Parasite Endogenous Metabolite Infection Cancer
    L-Canaline is a nonprotein amino acid stored in many leguminous plants. L-Canaline is a cytotoxic metabolite catalyzed by L-canavanine and its arginase. L-Canaline is a potent and irreversible inhibitor of ornithine aminotransferase. L-Canaline inhibits the growth of the malaria parasite Plasmodium falciparum with an IC50 of 297 nM. L-Canaline has anticancer and antiproliferative effects .
    L-Canaline
  • HY-125728
    Micrococcin P1

    		Bacterial Parasite HCV Infection
    Micrococcin P1 is a macrocyclic peptide antibiotic and is a potent hepatitis C virus (HCV) inhibitor with an EC50 range of 0.1-0.5 μM . Micrococcin P1 has in vitro antibacterial activity against Gram-positive bacterial strains. The MIC values of Micrococcin P1 against S. aureus 1974149, E. faecalis 1674621 and S. pyogenes 1744264 are 2 μg/mL, 1 μg/mL and 1 μg/mL, respectively . Micrococcin P1 is also a potent inhibitor of the malaria parasite Plasmodium falciparum .
    Micrococcin P1
  • HY-116392B
    DL-threo-PDMP hydrochloride

    		Glucosylceramide Synthase (GCS) Parasite Infection Endocrinology Cancer
    DL-threo-PDMP hydrochloride is a competitive glucosylceramide synthase (GCS) inhibitor and antimalarial agent. DL-threo-PDMP hydrochloride competitively inhibits the activity of GCS. DL-threo-PDMP hydrochloride restores cisplatin sensitivity in cisplatin-resistant testicular germ cell tumor cells. DL-threo-PDMP hydrochloride blocks the growth of ring-stage Plasmodium falciparum parasites .
    DL-threo-PDMP hydrochloride
  • HY-148315
    GLUT1-IN-2

    		GLUT Infection
    GLUT1-IN-2 (compound 17) is a GLUT1 inhibitor with an IC50 value of 12 μM. GLUT1-IN-2 shows inhibitory effect to Plasmodium falciparum hexose transporter PfHT with an IC50 value of 13 μM. GLUT1-IN-2 can be used for the research of infection .
    GLUT1-IN-2
  • HY-151574
    PfGSK3/PfPK6-IN-1

    		Ser/Thr Kinase Parasite GSK-3 Infection
    PfGSK3/PfPK6-IN-1 is a dual Plasmodium serine/threonine kinase inhibitor, with an IC50 of 97 nM against PfGSK3 and 8 nM against PfPK6 of Plasmodium falciparum. PfGSK3/PfPK6-IN-1 inhibits the proliferation of blood-stage parasites of Plasmodium falciparum 3D7. PfGSK3/PfPK6-IN-1 shows low cytotoxicity to hepatocytes at a concentration of 200 nM, and reduces cell viability at a concentration of 2 μM. PfGSK3/PfPK6-IN-1 is applicable to malaria-related research .
    PfGSK3/PfPK6-IN-1
  • HY-129651
    SHMT-IN-1

    		SHMT Infection
    SHMT-IN-1 is a Plasmodium falciparum Serine Hydroxymethyltransferase (PfSHMT) inhibitor with an IC50 of 350 nM. SHMT-IN-1 can be used for the research of malaria .
    SHMT-IN-1
  • HY-126323
    TCMDC-135051

    		Parasite Infection
    TCMDC-135051 is a highly selective and potent protein kinase PfCLK3 inhibitor with low off-target toxicity. TCMDC-135051 prevents trophozoite-to-schizont transition, disrupts transcription and reduces transmission to the mosquito vector. TCMDC-135051 has antiparasiticidal activity (EC50=320 nM) .
    TCMDC-135051
  • HY-117015
    Purfalcamine

    		Parasite Infection
    Purfalcamine is an orally active, selective Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) inhibitor with an IC50 of 17 nM and an EC50 of 230 nM. Purfalcamine has antimalarial activity and causes malaria parasites developmental arrest at the schizont stage .
    Purfalcamine
  • HY-117897
    CK-2-68
    1 Publications Verification

    		 Parasite Infection
    CK-2-68 is an inhibitor for complex III in protozoan mitochondrial respiratory chain, by targeting the alternative NADH dehydrogenase (NDH2) of the malarial parasite Plasmodium. CK-2-68 exhibits antimalaria efficacy, that inhibits Plasmodium falciparum infected erythrocytes with an IC50 of 40 nM .
    CK-2-68
  • HY-111817
    ACT-451840

    		Parasite Infection
    ACT-451840 is an orally active, potent and low-toxicity compound, showing activity against sensitive and resistant plasmodium falciparum strains. ACT-451840 targets all asexual blood stages of the parasite, has a rapid onset of action. ACT-451840 behaves in a way similar to artemisinin derivatives, with very rapid onset of action and elimination of parasite. ACT-451840 can be used for the research of malarial .
    ACT-451840
  • HY-17656
    C3361

    		Parasite Infection
    C3361 is a moderate specific Plasmodium falciparum hexose transporter 1 (PfHT1) and Plasmodium berghei hexose transporter 1 (PbHT1) inhibitor with Ki values of 8.6 and 9.4 μM. C3361 inhibits TgGT1 with a Ki of 82 μM. C3361 attenuates hepatic (IC50 = 15 μM) and ookinete development of P. berghei. C3361 can suppress the growth of blood-stage parasites. C3361 can be used for the research of infection, such as malaria .
    C3361
  • HY-126323B
    TCMDC-135051 hydrochloride

    		Parasite Infection
    TCMDC-135051 hydrochloride is a highly selective and potent protein kinase PfCLK3 inhibitor with low off-target toxicity. TCMDC-135051 hydrochloride prevents trophozoite-to-schizont transition, disrupts transcription and reduces transmission to the mosquito vector. TCMDC-135051 hydrochloride has antiparasiticidal activity (EC50=320 nM) .
    TCMDC-135051 hydrochloride
  • HY-N10928
    Lettowienolide

    		Parasite Infection
    Lettowienolide, a geranylbenzoquinonoid, exhibits mild in vitro activity against the Plasmodium falciparum malaria parasite (IC50~20 μg/mL) .
    Lettowienolide
  • HY-N9320
    13,21-Dihydroeurycomanone

    		Parasite Infection
    13,21-Dihydroeurycomanone, a natural compound isolated from Eurycoma longifolia root, possesses anti-parasite activity for Plasmodium falciparum and Toxoplasma gondii .
    13,21-Dihydroeurycomanone
  • HY-N10096
    Epoxyazadiradione

    		Parasite Infection
    Epoxyazadiradione is a limonoid purified from neem (Azadirachta indica) fruits. Epoxyazadiradione inhibits the tautomerase activity of MIF of both human (huMIF) and malaria parasites (Plasmodium falciparum (PfMIF) and Plasmodium yoelii (PyMIF)) non-competitively in a reversible fashion (Ki, 2.11-5.23 μM). Epoxyazadiradione has the potential against proinflammatory reactions induced by MIF of both malaria parasites and human .
    Epoxyazadiradione
  • HY-132171A
    DSM705 hydrochloride

    		Dihydroorotate Dehydrogenase Parasite Infection
    DSM705 hydrochloride, an orally active antimalarial compound, is a pyrrole-based Dihydroorotate Dehydrogenase (DHODH) inhibitor. DSM705 hydrochloride exhibits nanomolar potency against Plasmodium DHODH and Plasmodium parasites (IC50=95, 52 nM for P. falciparum and P. vivax DHODH, respectively), with no inhibition of mammalian DHODHs .
    DSM705 hydrochloride
  • HY-B0148R
    Risedronic acid (Standard)

    Risedronate (Standard)

    		 Parasite Reference Standards Apoptosis Infection Metabolic Disease Cancer
    Risedronic acid (Standard) (Risedronate (Standard)) is the analytical standard of Risedronic acid (HY-B0148). This product is intended for research and analytical applications. Risedronic acid (Risedronate) is a bisphosphonate and potent antiresorptive agent. Risedronic acid induces Apoptosis. Risedronic acid inhibits the transfer of farnesyl pyrophosphate groups to parasite proteins. Risedronic acid inhibits osteoclast-mediated bone resorption and alters bone metabolism. Risedronic acid inhibits blood-stage Plasmodium falciparum (IC50 of 20.3 μM).
    Risedronic acid (Standard)
  • HY-B0148S
    Risedronic acid-d4

    Risedronate-d4

    		 Isotope-Labeled Compounds Parasite Apoptosis Infection Metabolic Disease Cancer
    Risedronic acid-d4 (Risedronate-d4) is the deuterium labeled Risedronic acid (HY-B0148). Risedronic acid (Risedronate) is a bisphosphonate and potent antiresorptive agent. Risedronic acid induces Apoptosis. Risedronic acid inhibits the transfer of farnesyl pyrophosphate groups to parasite proteins. Risedronic acid inhibits osteoclast-mediated bone resorption and alters bone metabolism. Risedronic acid inhibits blood-stage Plasmodium falciparum (IC50 of 20.3 μM) .
    Risedronic acid-d4
  • HY-178728
    BION106

    		PROTACs Parasite Dihydrofolate reductase (DHFR) Infection
    BION106 is a dihydrofolate reductasethymidylate synthase (DHFR-TS) PROTAC degrader. BION106 exhibits extremely strong anti-malarial activity with a Ki and toxicity of 2.68 nM and 0.2 μM against Plasmodium falciparum, and > 100 μM and 44.2 μM in mammalian cells. BION106 can be used for the study of antimalarial parasites (Blue: Idasanutlin ligand (HY-15676); Pink: DHFR-TS ligand (HY-153007); Black: Linker (HY-W021401)) .
    BION106
  • HY-103397R
    Nanaomycin A (Standard)

    		Antibiotic Reference Standards DNA Methyltransferase Parasite Infection Cancer
    Nanaomycin A (Standard) is the analytical standard of Nanaomycin A. This product is intended for research and analytical applications. Nanaomycin A is the first selective DNMT3B inhibitor with an IC50 of 500 nM. Nanaomycin A, a quinone antibiotics, reactivates silenced tumor suppressor genes in human cancer cells[1]. Nanaomycin A inhibits in vitro growth of the human malaria parasite Plasmodium falciparum with an IC80 value of 33.1 nM[2].
    Nanaomycin A (Standard)
  • HY-163727
    MMV1557817

    		Parasite Infection
    MMV1557817 is an orally active and potent antimalarial compound. MMV1557817 is a selective, nanomolar inhibitor of both Plasmodium falciparum and Plasmodium vivax aminopeptidases M1 and M17, leading to inhibition of end-stage hemoglobin digestion in asexual parasites .
    MMV1557817
  • HY-145327
    Antimalarial agent 7

    		Na+/K+ ATPase Parasite Infection
    Antimalarial agent 7 is a potent inhibitor of PfATP4. PfATP4 is an essential ion pump on the parasite surface. Antimalarial agent 7 has the potential for the research of human malaria parasite, Plasmodium falciparum .
    Antimalarial agent 7
  • HY-174342
    ELQ-453

    		Cytochrome P450 Parasite Infection
    ELQ-453 is an inhibitor targeting the Qo site of the Plasmodium falciparum cytochrome bc1 complex (CytB) with an IC50 value of 0.57 nM. ELQ-453 blocks the mitochondrial function of the parasite, and suppresses Plasmodium infection in mosquitoes. ELQ-453 is promising for research of malaria .
    ELQ-453
  • HY-145912
    RYL-552S

    		Parasite Infection Inflammation/Immunology
    RYL-552S kills drug-resistant strains of Plasmodium falciparum. RYL-552S can efficiently kill asexual blood-stage parasites in vitro .
    RYL-552S
  • HY-148178
    MMV688533

    		Parasite Infection
    MMV688533 is an antimalarial agent. MMV688533 interferes with intracellular trafficking, lipid utilization, and endocytosis pathways in Plasmodium falciparum. MMV688533 rapidly kills asexual blood-stage Plasmodium falciparum and Plasmodium vivax parasites in vitro and reduces parasitemia in a Plasmodium falciparum NSG mouse model. MMV688533 can be used for the research of malaria .
    MMV688533
  • HY-153612
    MMV009085

    		GLUT Parasite Infection Inflammation/Immunology
    MMV009085 is a potent PfHT1 (Plasmodium falciparum hexose transporter)-specific inhibitor and a potential anti-malarial agent . MMV009085 is also a human glucose transporter inhibitor, it has high potency in inhibiting both glucose uptake (IC50: 2.6 μM in glucose uptake assay) and growth of the parasites (EC50: 1.23±0.04 μM against 3D7) .
    MMV009085
  • HY-N12538
    trans-Cinnamic anhydride

    		Parasite Infection
    trans-Cinnamic anhydride is a Parasite inhibitor tnat can be isolated from Cinnamomum zeylanicum and exhibits moderate activity against Plasmodium falciparum .
    trans-Cinnamic anhydride
  • HY-N8513
    Brevicompanine B

    		Parasite Infection
    Brevicompanine B, a diketopiperazine alkaloid, is an antiplasmodial agent. Brevicompanine B is active against the malaria parasite Plasmodium falciparum 3D7 IC50 of 35 mg/mL .
    Brevicompanine B
  • HY-172131
    Emoquine-1

    		Parasite Infection
    Emoquine-1 is an orally active and potent antimalarial drug. Emoquine-1 is efficient against multidrug-resistant Plasmodium parasites, including the Artemisinin-resistant quiescent stage. Emoquine-1 is active against proliferative P. falciparum with IC50 values of 20-55 nM. Emoquine-1 is a candidate to fight Plasmodium parasites resistant to artemisinin-based combination therapies (ACTs) with a capacity to eliminate persistent parasites .
    Emoquine-1
  • HY-173567
    WJM664

    		Parasite Infection
    WJM664 is a potent Plasmodium falciparum PfATP4 inhibitor. WJM664 shows strong activity against malaria parasites. WJM664 blocks gamete development and transmission to mosquitoes by inhibiting PfATP4-mediated Na +-dependent ATPase activity, and acts on multiple stages of the malaria parasite life cycle .
    WJM664
  • HY-B0529AR
    Azlocillin sodium salt (Standard)

    Sodium azlocillin (Standard)

    		 Reference Standards Bacterial Parasite Antibiotic Infection
    Azlocillin (sodium salt) (Standard) is the analytical standard of Azlocillin (sodium salt). This product is intended for research and analytical applications. Azlocillin sodium salt (Sodium azlocillin), a semisynthetic penicillin, is a broad spectrum β-lactam antibiotic. Azlocillin sodium salt shows antipseudomonal activity, and also potent against the malarial parasite Plasmodium falciparum .
    Azlocillin sodium salt (Standard)
  • HY-P5344
    Dabcyl-LNKRLLHETQ-Edans

    Fluorigenic PEXEL peptide

    		 Parasite Others
    Dabcyl-LNKRLLHETQ-Edans (Fluorigenic PEXEL peptide) is a biological active peptide. (This FRET substrate peptide for Plasmepsin V (PMV) is derived from the conserved Plasmodium Export Element (PEXEL) motif of Histidine-Rich Protein II (HRPII). PMV is an ER aspartic protease that recognizes and cleaves the RXL sequence within the PEXEL motif of proteins exported by human malaria parasite Plasmodium falciparum, allowing them to translocate into host erythrocytes.)
    Dabcyl-LNKRLLHETQ-Edans
  • HY-159479
    PfSUB1-IN-1

    		Parasite Infection
    PfSUB1-IN-1 (compound 4c) is a plasmodium falciparum subtilisin-like serine protease 1 (PfSUB1) Inhibitor (IC50: 15 nM). PfSUB1 is an antimalarial target. PfSUB1-IN-1 inhibits the growth of a genetically modified P. falciparum line expressing reduced levels of PfSUB1 13-fold more efficiently compared to a wild-type parasite line .
    PfSUB1-IN-1
  • HY-116535A
    DL-threo-PPMP hydrochloride

    		Parasite Infection
    DL-threo-PPMP hydrochloride is an inhibitor of sphingosine synthetase in Plasmodium falciparum. DL-threo-PPMP hydrochloride inhibits the activity of sphingosine synthetase (sphingosine synthetase) by binding to a substrate that mimics sphingosine. This inhibition leads to a rapid decline in sensitive sphingomyelin synthase (SSS) activity, selectively disrupting the interconnected tubular network of TVM in the cytoplasm of the host cell, and this inhibition also blocks the proliferation of the parasite. DL-threo-PPMP hydrochloride can be used in the study of malaria parasite biology and the search for new antimalarial strategies .
    DL-threo-PPMP hydrochloride
  • HY-159963
    PfCLK3-IN-1

    		Parasite Infection
    PfCLK3-IN-1 (Compound 4) is a covalent inhibitor for Plasmodium falciparum CLK3 (Pf CLK3) under alkaline conditions with an pEC50 of 7.1. PfCLK3-IN-1 reduces mature gametocytes in sexual stage parasites, and prevents transmission. PfCLK3-IN-1 inhibits P. falciparum Dd2-B2 clone with an IC50 of 239.5 nM .
    PfCLK3-IN-1
  • HY-103353A
    SID 26681509 quarterhydrate
    5 Publications Verification

    		 Cathepsin Parasite Infection Cancer
    SID 26681509 quarterhydrate is a potent, reversible, competitive, and selective inhibitor of human cathepsin L with an IC50 of 56 nM. SID 26681509 quarterhydrate inhibits in vitro propagation of malaria parasite Plasmodium falciparum and inhibits Leishmania major with IC50s of 15.4 μM and 12.5 μM, respectively. SID 26681509 quarterhydrate shows no inhibitory activity against cathepsin G .
    SID 26681509 quarterhydrate
  • HY-A0130R
    Sulfalene (Standard)

    Sulfametopyrazine (Standard); AS-18908 (Standard)

    		 Reference Standards Parasite Infection
    Sulfalene (Standard) is the analytical standard of Sulfalene. This product is intended for research and analytical applications. Sulfalene (Sulfametopyrazine; AS-18908) is an orally active antimalarial agent. Sulfalene competes for para-aminobenzoic acid binding in plasmodial folic acid synthesis. Sulfalene, combined with Trimethoprim (HY-B0510), clears parasites, resolves fever, and resists induced resistance against drug-sensitive and drug-resistant Plasmodium falciparum. Sulfalene can be used for the research of acute falciparum malaria and Schistosoma mansoni infection .
    Sulfalene (Standard)
  • HY-183238
    Antimalarial agent 61

    		Parasite Infection
    Antimalarial agent 61 is an antimalarial agent. Antimalarial agent 61 disrupts hemoglobin breakdown in Plasmodium falciparum asexual blood stage trophozoites. Antimalarial agent 61 exerts antiplasmodial activity against Chloroquine (HY-17589A)-sensitive Plasmodium falciparum parasites. Antimalarial agent 61 can be used for the research of malaria .
    Antimalarial agent 61
  • HY-149960
    Antiparasitic agent-17

    		Parasite Infection
    Antiparasitic agent-17 (compound 5u) is an orally active antiparasitic agent. Antiparasitic agent-17 inhibits Chloroquine sensitive (Pf3D7) and Chloroquine resistant (PfK1) strain with IC50s of 0.96 μM and 1.67 μM, respectively .
    Antiparasitic agent-17
  • HY-W078844
    PfDHODH-IN-2

    		Dihydroorotate Dehydrogenase Parasite Infection
    PfDHODH-IN-2, a dihydrothiophenone derivative (Compound 11), is a potent Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor with an IC50 of 1.11 µM. PfDHODH-IN-2 acts as an antimalarial agent and can be used for the research of malaria .
    PfDHODH-IN-2
  • HY-126323A
    TCMDC-135051 TFA

    		Parasite Infection
    TCMDC-135051 TFA is a highly selective and potent protein kinase PfCLK3 inhibitor with low off-target toxicity. TCMDC-135051 TFA prevents trophozoite-to-schizont transition, disrupts transcription and reduces transmission to the mosquito vector. TCMDC-135051 TFA has antiparasiticidal activity (EC50=320 nM) .
    TCMDC-135051 TFA
  • HY-182683
    MMV085203

    		Parasite TrxR Reactive Oxygen Species (ROS) Infection
    MMV085203 is a potent Plasmodium falciparum inhibitor, with a PfTrxR EC50 of 900 nM. MMV085203 exerts potent antimalarial activity against both blood‑stage and sexual‑stage Plasmodium falciparum parasites, with superior efficacy toward clinical isolates of high clonal diversity. MMV085203 modulates parasite redox homeostasis, induces ROS production, and elevates mitochondrial TCA cycle intermediates. MMV085203 can be used for the research of malaria .
    MMV085203
  • HY-169194
    Antimalarial agent 44

    		Parasite Infection
    Antimalarial agent 44 (Compound 3) is an antimalarial agent against parasite. Antimalarial agent 44 has a good permeability across MDCK-MDR1 cell monolayers and a high clearance by mouse liver microsomes .
    Antimalarial agent 44

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: